Infinity Pharmaceuticals Inc. (INFI) and Bellerophon Therapeutics Inc. (NASDAQ:BLPH) Comparing side by side

This is therefore a comparing of the risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation in Infinity Pharmaceuticals Inc. (NASDAQ:INFI) and Bellerophon Therapeutics Inc. (NASDAQ:BLPH). The two are both Biotechnology companies that compete with one another.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Infinity Pharmaceuticals Inc. 22.15M 4.62 11.25M 1.25 1.28
Bellerophon Therapeutics Inc. N/A 0.00 2.81M -0.41 0.00

Demonstrates Infinity Pharmaceuticals Inc. and Bellerophon Therapeutics Inc. earnings per share (EPS), gross revenue and valuation.


Table 2 has Infinity Pharmaceuticals Inc. and Bellerophon Therapeutics Inc.’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Infinity Pharmaceuticals Inc. -50.79% -20.8% -18.2%
Bellerophon Therapeutics Inc. 0.00% 0% -64.8%

Volatility & Risk

Infinity Pharmaceuticals Inc. is 122.00% more volatile than Standard and Poor’s 500 because the stock has a beta of 2.22. Competitively, Bellerophon Therapeutics Inc. is 104.00% less volatile than Standard and Poor’s 500, because of the -0.04 beta.


Infinity Pharmaceuticals Inc.’s Current Ratio and Quick Ratio are 10.7 and 10.7 respectively. The Current Ratio and Quick Ratio of its competitor Bellerophon Therapeutics Inc. are 2.5 and 2.5 respectively. Infinity Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to Bellerophon Therapeutics Inc.

Analyst Recommendations

In next table is given Infinity Pharmaceuticals Inc. and Bellerophon Therapeutics Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Infinity Pharmaceuticals Inc. 1 1 1 2.33
Bellerophon Therapeutics Inc. 0 0 1 3.00

Infinity Pharmaceuticals Inc. has an average target price of $3, and a 66.67% upside potential. Competitively Bellerophon Therapeutics Inc. has an average target price of $3, with potential upside of 334.78%. The data provided earlier shows that Bellerophon Therapeutics Inc. appears more favorable than Infinity Pharmaceuticals Inc., based on analyst view.

Insider & Institutional Ownership

Institutional investors owned 54.9% of Infinity Pharmaceuticals Inc. shares and 50.6% of Bellerophon Therapeutics Inc. shares. About 1.1% of Infinity Pharmaceuticals Inc.’s share are owned by insiders. On the other hand, insiders owned about 7.8% of Bellerophon Therapeutics Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Infinity Pharmaceuticals Inc. -3.03% 32.23% 16.79% -21.57% -16.67% 35.59%
Bellerophon Therapeutics Inc. -2.42% -8.49% -27.52% -20.98% -61.88% -19.14%

For the past year Infinity Pharmaceuticals Inc. had bullish trend while Bellerophon Therapeutics Inc. had bearish trend.


On 7 of the 12 factors Infinity Pharmaceuticals Inc. beats Bellerophon Therapeutics Inc.

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. Its lead product candidate includes IPI-549 an orally administered immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma) is in Phase 1 clinical study. The company has a license agreement with Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib, a selective inhibitor of the PI3K delta and gamma isoforms, including DUO study that is in randomized Phase III clinical study for patients with relapsed/refractory chronic lymphocytic leukemia and products containing duvelisib; Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; and Takeda Pharmaceutical Company Limited to develop and commercialize duvelisib. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases. Its product candidates are INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and in Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.